Phaseline

Companies › Acacia Pharma

Acacia Pharma: clinical trials, targets and expected readouts

1 active drug program in 12 registered trials: 11 Phase 4, 1 Phase 2; Cardiovascular, Gastroenterology, Infectious disease, Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Remimazolam
GABA-A receptor; anion channel positive allosteric modulator
GABRA1, GABRB2, GABRG2, GABRB3, GABRA4Phase 2Pediatric ALL; Benzodiazepines; Cataract Surgery; Sedation for Diagnostic Gastroscopy …Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04532606RemimazolamPhase 4BenzodiazepinesOncologyOct 2025
NCT05980117RemimazolamPhase 4Cataract SurgeryOphthalmologyDec 2025
NCT06614036RemimazolamPhase 4Sedation for Diagnostic GastroscopyGastroenterologyDec 2025
NCT06784479RemimazolamPhase 4Sedative Effect During Drug-induced Sleep EndoscopyRespiratoryMar 2026
NCT07118579RemimazolamPhase 4Tonsillectomy With or Without AdenoidectomyOtherAug 2026
NCT07395596RemimazolamPhase 4Pulmonary InfectionInfectious diseaseDec 2026
NCT06777758RemimazolamPhase 4Postoperative ComplicationsPsychiatryDec 2026
NCT07046364RemimazolamPhase 4PediatricOtherJan 2027
NCT07789275RemimazolamPhase 4Intraoperative HypotensionCardiovascularJul 2027
NCT07717684RemimazolamPhase 4Intravenous AnesthesiaGastroenterologyAug 2027
NCT04851717RemimazolamPhase 2Pediatric ALLOncologyOct 2027
NCT05728775RemimazolamPhase 4AnesthesiaOtherDec 2027

From the company's SEC filings

Complete response letters from FDA

Targets

GABRA1 (1) GABRB2 (1) GABRG2 (1) GABRB3 (1) GABRA4 (1)

Companies with the same targets

Ono Pharmaceutical Lipocine UCB Biopharma SRL Haisco Pharmaceutical Group SK Life Science Sedana Medical Seaport Therapeutics Neurodawn Pharmaceutical Umecrine Cognition

Companies built like this

Guangzhou Novaken Pharm Sedana Medical Lipocine Biocodex Ascension Health

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.